Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexed glucose-6-phosphate isomerase (G6PI).
In K/BxN mice, anti-glucose-6-phosphate isomerase (G6PI) IgG antibodies (Abs) cause joint-specific inflammation and destruction. Anti-G6PI Abs are also present in humans with inflammatory arthritis, especially among patients with rheumatoid arthritis (RA). A contributing factor to the induction of such autoantibodies may be upregulated expression of the corresponding antigen G6PI in affected tissues and/or increased levels of G6PI in the circulation. To determine G6PI levels and the presence of free G6PI and/or G6PI-containing immune complexes in sera and synovial fluids (SF) of patients with different arthritides, serum and SF obtained concomitantly from 91 clinically well-defined arthritis patients were assessed in a blinded manner for G6PI enzymatic assay and for G6PI protein concentration by ELISA. Sera and SF from patients with immune-based inflammatory arthritis contained significantly higher levels of G6PI enzymatic activity compared to sera or SF from patients with non-immune-based inflammatory arthritis or healthy controls. In addition, significantly higher levels of total G6PI protein concentration (including both enzymatically active and inactive forms) were present in sera of RA patients vs. those with other immune-based or non-immune-based inflammatory arthritis.G6PI in sera and SF were present both as G6PI-containing immune complexes and as free G6PI, with the majority of free G6PI existing as tetramers with lesser amounts of dimers and monomers. Levels of G6PI enzymatic activity in the sera of most immune-based inflammatory arthritis patients are elevated and may reflect ongoing inflammation and cell destruction. The high serum levels of enzymatically inactive forms of G6PI in RA relative to those in other arthritic diseases are partially due to G6PI-containing immune complexes, a portion of which also contains C1q. Overall, our study supports the notion that elevated G6PI levels present in patients with immune-based inflammatory arthritis may contribute to elevated levels of anti-G6PI Abs and G6PI/anti-G6PI immune complexes. This, in turn, may trigger production of proinflammatory cytokines and perpetuate the inflammatory process.
Schaller
Monica
M
Department of Immunology, IMM2, The Scripps Research Institute, La Jolla, CA 92037, USA.
Stohl
William
W
Benoit
Vivian
V
Tan
Soon-Min
SM
Johansen
Lene
L
Ditzel
Henrik J
HJ
D001168:Arthritis / Q000097:blood* / Q000378:metabolism; D015331:Cohort Studies; D015922:Complement C1q / Q000378:metabolism; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005956:Glucose-6-Phosphate Isomerase / Q000097:blood* / Q000378:metabolism; D006801:Humans; D007107:Immune System; D007249:Inflammation / Q000378:metabolism*; D007596:Joints / Q000473:pathology*; D008297:Male; D011994:Recombinant Proteins / Q000737:chemistry; D013582:Synovial Fluid / Q000378:metabolism*
D011994:Recombinant Proteins; D015922:Complement C1q; D005956:Glucose-6-Phosphate Isomerase